Previous 10 | Next 10 |
2024-02-13 00:39:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...
2024-02-12 16:46:59 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Q4 2023 Earnings Preview Biogen scraps Aduhelm,...
Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to...
2024-02-12 11:21:47 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen scraps Aduhelm, will focus on other Alzheimer's drugs ...
2024-02-11 11:23:00 ET Summary This week, traders will have a lot of economic data to digest, including retail sales, manufacturing measures, jobless claims, and the consumer price index. The market is now pricing in a 16% chance of a March rate reduction by the Fed, but odds top ...
2024-02-11 08:00:00 ET As the quarterly earnings season continues, the upcoming week promises a flurry of reports from industry titans spanning a diverse array of sectors. From energy to semiconductors, cybersecurity to consumer packaged goods, the market will be abuzz with updates fr...
2024-02-11 01:25:00 ET Summary I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 M. Anbogen Therapeutics raised $12.5M in a Series A funding round. to advance its two lead drug candidates. Bayer signed a non-binding Letter of Intent to m...
2024-02-09 15:00:09 ET More on the markets SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In My Current View Of The S&P 500 Index: February 2024 Edition (Technical Analysis) 2024 Analyst Outlook: Yiannis Zourmpanos On Cautious Optimism For The N...
2024-02-06 06:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...